- General population
- Infants (<1 year)
- Adolescents (12-17 years)
- Children (1-11 years)
- Community
- Household
- SARS-CoV-2
- Respiratory syncytial virus
- Influenza virus
- Respiratory syncytial virus infection
- Influenza
- COVID-19
Setting: Community
A research environment where studies are conducted outside of clinical or laboratory settings, focusing on real-world populations
- General population
- Infants (<1 year)
- Community
- Respiratory syncytial virus
- Respiratory syncytial virus infection
- Pharmacological intervention
- Monoclonal antibodies
- Nirsevimab
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Adolescents (12-17 years)
- Children (1-11 years)
- Community
- Monkeypox virus
- Mpox
- Sexually transmitted infection
- Adults (18-64 years)
- General population
- Community
- SARS-CoV-2
- Post-COVID-19
- Colchicine
- Antihistamines
- Rivaroxaban
- Adults (18-64 years)
- Outpatient clinic
- Community
- Primary care
- SARS-CoV-2
- Post-COVID-19
- Pharmacological intervention
- Immunomodulator
- Colchicine
- Metformin
- Pregnant women
- Community
- Arbovirus
- Vector-borne disease
- Zika virus
- Venezuelan equine encephalitis virus
- Arboviral disease
- Vector-borne disease
- Adults (18-64 years)
- General population
- Infants (<1 year)
- Children (1-11 years)
- Pregnant women
- Community
- Arbovirus
- Vector-borne disease
- Zika virus
- Arboviral disease
- Vector-borne disease
- Blood sample
- Urine sample
- Hair
- Saliva
- Semen
- Vaginal fluids
- Adults (18-64 years)
- Elderly (≥65 years)
- People at high risk of STIs
- PrEP users
- Hospital
- Community
- Primary care
- Chlamydia trachomatis
- Neisseria gonorrhoeae
- Treponema pallidum
- Sexually transmitted infection
- Syphilis
- Pharmacological intervention
- PrEP-bSTI
- Adults (18-64 years)
- General population
- Pregnant women
- Community
- Chlamydia trachomatis
- Sexually transmitted infection
- Adults (18-64 years)
- Elderly (≥65 years)
- Community
- Arbovirus
- Chikungunya virus
- Vector-borne
- Arboviral disease
- Vector-borne disease
- Post-acute infection syndrome
- Adults (18-64 years)
- Elderly (≥65 years)
- Travelers
- Community
- Telemedicine
- Arbovirus
- Chikungunya virus
- Vector-borne
- Dengue virus
- West Nile virus
- Arboviral disease
- Vector-borne disease
- Post-acute infection syndrome
- Non pharmacological intervention
- Digital health
- Adults (18-64 years)
- Elderly (≥65 years)
- Community
- Arbovirus
- Chikungunya virus
- Vector-borne
- Arboviral disease
- Vector-borne disease
- Post-acute infection syndrome